Want to see AYTU full AI Analyst Report?
Top Page
Aytu BioScience
(NASDAQ:AYTU)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▼(-23.08% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by deteriorating profitability and declining revenue, alongside weak technicals (below key moving averages and negative MACD). These are partially offset by a relatively low-leverage balance sheet, recently positive TTM free cash flow, and a cautiously optimistic earnings call driven by early EXXUA launch momentum.
Positive Factors
Low Financial Leverage
A very low debt-to-equity (~0.05) provides durable financial flexibility, lowering interest burden and refinancing risk. This conservative leverage profile helps the company fund launch investments and absorb operating losses in the near term without heavy reliance on new debt financing.
Negative Factors
Declining Revenue Trend
Revenue contraction on a trailing‑twelve‑month basis signals structural headwinds from legacy portfolio erosion and payer dynamics. Sustained top‑line declines reduce operating leverage, making it harder for a growing product to offset lost legacy sales and to achieve durable profitability within a 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
A very low debt-to-equity (~0.05) provides durable financial flexibility, lowering interest burden and refinancing risk. This conservative leverage profile helps the company fund launch investments and absorb operating losses in the near term without heavy reliance on new debt financing.
Read all positive factors
Aytu BioScience Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Data provided by:
The Fly
The FlyAytu BioScience (AYTU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.29M
Dividend YieldN/A
Average Volume (3M)314.73K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth-18.24%
EPS Growth-2264.65%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-4.29
Shares Outstanding10,733,208
10 Day Avg. Volume289,104
30 Day Avg. Volume314,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit0.38
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$9.50Price Target Upside265.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$53.75M
Aytu BioScience Business Overview & Revenue Model
Company Description
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes s...
How the Company Makes Money
Aytu generates revenue primarily from net product sales of its prescription pharmaceuticals in the United States. The company’s revenue model is typical of a commercial-stage specialty pharma business: it sells branded products to customers such a...
Aytu BioScience Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Sep 29, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive picture: EXXUA's initial commercial launch shows strong early traction with accelerating prescription and shipment trends, encouraging payer coverage and attractive unit economics, and the RxConnect program appears to be reducing access friction. Offsetting this are significant year-over-year declines in legacy revenue, a quarter with a net loss and negative adjusted EBITDA, an inventory write-down, and near-term gross-to-net and cash-use volatility while the launch investment continues. Given the early-stage but tangible commercial progress balanced against meaningful near-term financial headwinds, the tone is cautiously optimistic but still transitional.Positive Updates
Strong Early EXXUA Launch Momentum
EXXUA generated $2.4M in net revenue in the quarter (first meaningful commercial quarter) with more than 1,300 prescriptions written in Q3 and continued growth into April (over 920 prescriptions). Prescriptions progressed monthly from ~200 (Jan) to ~400 (Feb) to >700 (Mar) and +26% month-over-month in April.
Negative Updates
Overall Revenue Decline Year-over-Year
Total net revenue for Q3 was $12.4M versus $18.5M in the prior year period, a decrease of $6.0M or 33% year-over-year as the company transitions commercial focus to EXXUA.
Read all updates
Q3-2026 Updates
Positive
Negative
Strong Early EXXUA Launch Momentum
EXXUA generated $2.4M in net revenue in the quarter (first meaningful commercial quarter) with more than 1,300 prescriptions written in Q3 and continued growth into April (over 920 prescriptions). Prescriptions progressed monthly from ~200 (Jan) to ~400 (Feb) to >700 (Mar) and +26% month-over-month in April.
Read all positive updates
Company Guidance
They did not give formal guidance but laid out a clear financial framework and near‑term operating expectations: EXXUA contributed $2.4M in Q3 with >1,300 prescriptions and >450 unique prescribers in the quarter (3,335 units sold in Q3 — 1,807 30‑count and 1,528 titration — and 3,881 units since launch), April topped ~920 scripts and >1,300 units shipped (26% month‑over‑month script growth, 51% unit growth), and early RxConnect metrics show a >70% prior‑auth approval rate plus a no‑cost 14‑day titration and guaranteed month‑1/2 coverage for commercially insured patients; financially they expect EXXUA unit economics of roughly 31% COGS (~69% gross contribution margin), mid‑ to high‑60% gross margins over time, and a near‑term path to profitability as EXXUA scales, while ongoing quarterly sales & marketing spend is expected to be $6–7M and G&A $5–5.3M (with Q4 digital spend rising $1–2M and speaker/medical education $200–300K); Q3 company metrics included net revenue $12.4M (down 33% YoY), gross margin 61% (≈67% excluding a $700K inventory write‑down), adjusted EBITDA of –$2.8M, net loss $5.6M ($0.53/sh), cash $26.7M, revolver $10.4M, total debt ~$11.4M and stockholders’ equity $35.1M after a $26.4M warrant reclassification.Aytu BioScience Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
46
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.60M | 66.38M | 65.18M | 107.40M | 96.67M | 65.63M |
| Gross Profit | 35.38M | 45.83M | 49.05M | 66.63M | 50.28M | 29.20M |
| EBITDA | -27.32M | -4.67M | 1.41M | -3.27M | -27.96M | -29.04M |
| Net Income | -34.05M | -13.56M | -15.84M | -17.05M | -108.78M | -58.29M |
Balance Sheet | ||||||
| Total Assets | 111.69M | 124.18M | 118.86M | 137.84M | 137.62M | 265.67M |
| Cash, Cash Equivalents and Short-Term Investments | 26.71M | 30.95M | 20.01M | 22.98M | 19.36M | 49.65M |
| Total Debt | 22.94M | 22.94M | 16.42M | 30.43M | 18.19M | 30.97M |
| Total Liabilities | 76.55M | 105.21M | 91.14M | 98.48M | 93.31M | 128.10M |
| Stockholders Equity | 35.14M | 18.97M | 27.72M | 39.36M | 44.31M | 137.57M |
Cash Flow | ||||||
| Free Cash Flow | 1.64M | -5.17M | -1.72M | -5.13M | -28.82M | -25.96M |
| Operating Cash Flow | 1.68M | -1.94M | -1.39M | -5.13M | -28.82M | -25.96M |
| Investing Cash Flow | -3.03M | -2.56M | -329.00K | -117.00K | -3.25M | -2.78M |
| Financing Cash Flow | 9.90M | 15.44M | -1.26M | 8.87M | 1.53M | 30.31M |
Aytu BioScience Technical Analysis
Negative
2.60
Price Trends
2.32
Negative
2.42
Negative
2.37
Negative
Market Momentum
-0.03
Negative
45.73
Neutral
40.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Negative. The current price of 2.6 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.32, and above the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 40.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AYTU.
Aytu BioScience Risk Analysis
Aytu BioScience disclosed 59 risk factors in its most recent earnings report. Aytu BioScience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aytu BioScience Peers Comparison
UnderperformOutperform
Sector (51)
AYTU
Aytu BioScience
2.17
-0.01
-0.46%
TXMD
TherapeuticsMD
2.11
0.95
81.90%
COSM
Cosmos Holdings
0.17
-0.25
-59.05%
GELS
Gelteq Limited
0.62
-1.11
-64.16%
Aytu BioScience Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Aytu BioScience Amends Warrants, Modifying Security Holder Rights
Neutral
Apr 2, 2026
Aytu BioScience reported that it amended certain outstanding warrants in a transaction structured as a private exchange of securities rather than a registered public offering under the Securities Act of 1933. The company relied on exemptions from ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.